Corgenix Ebola detection research wins award at AACC expo

Corgenix Medical Corporation, a diagnostic kit developer, announced on Wednesday that it received an award at the American Association for Clinical Chemistry's (AACC) annual meeting for a poster abstract on Ebola detection.

The Best Annual Meeting Abstract Award was presented to Corgenix for the poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection." Abby Jones, a Corgenix research associate, presented the abstract during the AACC Annual Meeting and Clinical Lab Expo 2014 in Chicago, according to a Corgenix press release.

The award is given in recognition of outstanding research for posters and abstracts presented at the annual meeting.

"We're pleased to accept this prestigious award and we must also recognize our academic research and industry partners at the Viral Hemorrhagic Fever Consortium (VHFC) who have helped to make this possible," Douglass Simpson, the president and CEO of Corgenix, said. "We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa and other biologic agents. Rapid accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats."

Simpson said point-of-care testing will be needed in the future to rapidly identify and treat viral hemorrhagic fevers like Marburg, Lassa and Ebola.

Corgenix and VHFC recently received a three-year, $2.9 million grant from the National Institutes of Health to continue developing an Ebola rapid diagnostic test kit. Corgenix develops and manufactures specialized diagnostic kits for vascular diseases, bone and joint disorders, immunology disorders, and viral hemorrhagic diseases.

Organizations in this Story

National Institutes of Health

Want to get notified whenever we write about National Institutes of Health ?
Next time we write about National Institutes of Health, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.